This site is fictional demo content. It is not real news or affiliated with any real organization. Do not treat it as fact or professional advice.

NextPaper Logo
nextpaper.ccCYBER CHRONICLE
RSS
EN中文

Full article

FULL TEXT

View this issue
BriefMEDTECH

Cancer Early Warning E-Skin Patch CancerStamp Validates in 1,000-Person Cohort: Asymptomatic Cancer Screening via Sweat Metabolites

Biosensor company OncoSens's e-skin patch CancerStamp completes a 1,200-person prospective cohort study, identifying 5 common cancers in asymptomatic stages by analyzing combined patterns of 12 sweat metabolite markers, achieving 78% overall sensitivity and 92% specificity.

Cancer Early Warning E-Skin Patch CancerStamp Validates in 1,000-Person Cohort

Biosensor company OncoSens published results from its 1,200-person prospective cohort study of CancerStamp on August 29. The patch continuously collects 12 metabolite markers from the wearer's sweat, using an AI model to analyze time-series changes in marker concentration patterns to identify 5 common cancers — lung, colorectal, breast, liver, and pancreatic — in asymptomatic stages.

The study enrolled 1,200 volunteers aged 40-65 who wore CancerStamp for 6 months. Results showed 78% overall sensitivity and 92% specificity, with pancreatic cancer achieving the highest sensitivity at 85%. OncoSens plans to submit for FDA approval in 2029.